Seralutinib Update: U.S. Approval Filing Planned
Back in March, we noted that Gossamer Bio’s phase 3 clinical trial of seralutinib (a drug for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease) didn’t meet its primary endpoint, causing a steep drop in its stock price. The study had some promising results: it showed a potentially good response to seralutinib, but some locations had an unusually good response to the placebo, which may have affected the analysis. Despite the s
Canadians need Connected Care: Supporting Bill S-5
Only 29% of physicians can share patient information outside their practice. Less than half (47%) of Canadians have accessed their own electronic health records. This disconnect has real consequences: duplicated tests, delayed diagnoses, and prescriptions without a full picture. Bill S-5 can help fix this: It prohibits practices that lock patient information in systems that can’t communicate with each other. It requires common standards for health information sharing. This le
.jpg)
